You are here » Home » Companies » Company Overview » Suven Life Sciences Ltd

Suven Life Sciences Ltd.

BSE: 530239 Sector: Health care
NSE: SUVEN ISIN Code: INE495B01038
BSE 00:00 | 22 Feb 235.30 1.05
(0.45%)
OPEN

237.00

HIGH

240.10

LOW

233.05

NSE 00:00 | 22 Feb 234.60 0.85
(0.36%)
OPEN

235.40

HIGH

239.20

LOW

232.40

OPEN 237.00
PREVIOUS CLOSE 234.25
VOLUME 37058
52-Week high 337.70
52-Week low 163.30
P/E 20.71
Mkt Cap.(Rs cr) 2,995
Buy Price 234.00
Buy Qty 50.00
Sell Price 234.95
Sell Qty 15.00
OPEN 237.00
CLOSE 234.25
VOLUME 37058
52-Week high 337.70
52-Week low 163.30
P/E 20.71
Mkt Cap.(Rs cr) 2,995
Buy Price 234.00
Buy Qty 50.00
Sell Price 234.95
Sell Qty 15.00

Suven Life Sciences Ltd. (SUVEN) - Chairman Speech

Company chairman speech

AT SUVEN EVERY DAY IS EXCITING. EACH DAY BRINGS WITH IT NEW CHALLENGES AND LEARNINGOPPORTUNITIES. AND IT IS THIS CONCOCTION OF CHALLENGES AND OPPORTUNITIES THAT OPENS NEWVISTAS OF GROWTH.

Dear shareholders

Fiscal 2017-18 was another year of healthy growth in business pro3 ts and pro3tability as some of our initiatives yielded interesting returns. These milestones holdspecial signi3 cance in Suven's journey as they strengthen the Company's ability todeliver value to shareholders. Fiscal 2017-18 was interesting for it was a period of upsand downs. In the first half our business and pro3 ts took a dip. While in the secondhalf fortunes turned in our favour to close the year with a positive momentum. What I amtrying to get at is that Suven is not akin to other companies where quarterly numbers canbe extrapolated for the whole.

Because Suven is not just a manufacturing company but a Contract Research Company andthe results of research leads to manufacturing activity and then supplies to ourcustomers.

Because Suven is not in the market share game it is in the market size space whereevery new development only promises to expand the pharmaceutical sector's horizon. Becausefor Suven surprises happen even as it passionately works to transform its business modelfrom the perceived unpredictable to the increasingly stable. Fiscal 2017-18 in my mind isa typical case of surprises. The first was a negative one in the first half of the yearwhen supply of an intermediate to a specialty chemical customer dropped owing togenericisation and consequent price erosion. And in the second half of the year ourperformance was bolstered by the continued supply for commercial products and also aninitial commercial order for a women's health product which is readying for NDAsubmission.

These things will continue to happen as we move along. And we are accustomed to thisand hence unperturbed. But our learning from these events is to continue to strengthen allour revenue verticals with new growth levers that promise to sustain business momentumdespite the unannounced surprises.

For example in the specialty chemical space we are working on three other novelmolecules which if and when approved will position this business segment as an importantrevenue driver. Further we are increasing our ANDA 3 lings in a phased manner over thenext 3-4 years which when approved will provide stable revenue over the medium term. Andmost importantly we will continue to reap the benefits from the commercial supplies forthe next few years.This I expect will provide a healthy growth opportunity over themedium-term even as two other approved molecules are awaiting a market launch. In anutshell then to be part of the Suven family you need to have trust and patience. Trustin our expertise to develop and abilities to deliver. Patience because our initiativesare long-gestation projects — longer than other pharmaceutical companies as we delveinto the unknown which has its own set of challenges. Creation of new molecules by ourcustomers does not happen in a day. But when it does the returns from the project faroutweigh the e3 ort and perseverance invested in the project. At Suven every day isexciting. Each and every day brings with it new challenges and learning opportunities. Andit is this concoction of challenges and opportunities that opens new vistas of growth.Hence at Suven growth is always in progress.

Warm regards

Venkat Jasti Chairman & CEO